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Acute lymphoblastic leukemia bearing the Philadelphia chromosome is among the most
difficult types of ALL to cure. However, the advent of targeted tyrosine kinase inhibitor
(TKI) imatinib has ushered in a new era of treatments that have the potential to be less
toxic to patients. Integrins and tyrosine kinases play important roles in mediating and trans-
ducing signals for cell survival and suppressing apoptosis. Focal adhesion kinase (FAK) is a
non-receptor type tyrosine kinase that is constitutively activated in Ph+ ALL. We sought to
investigate the specificity of integrin α5β1 (VLA-5) on Ph+ leukemia by its expression and
function.We foundVLA-5 expression increases after serum starvation. Integrin α5 inhibitory
antibody inhibited adhesion of Ph+ leukemia to human fibronectin and acted synergisti-
cally with imatinib to induce Ph+ leukemia cell apoptosis. We used different strategies to
block integrin signaling and knocked down the expression of integrin VLA-5 to observe the
effect on proliferation and engraftment of Ph+ leukemia cells in immunodeficient mice.
We found that blocking integrin activity by incubating Ph+ leukemia cells with disintegrin,
a peptide inhibitor of integrins, or α5 inhibitory antibody, or knocking down the α5 integrin
subunit impaired and delayed the engraftment of Ph+ leukemia in immunodeficient mice.
We then treated mice xenografted with Ph+ leukemia cells with the FAK inhibitorTAE226 in
combination with a BCR–ABLTKI nilotinib. While 2 weeks of treatment withTAE226 alone
did not significantly inhibit leukemia growth in mice, TAE226 in combination with nilotinib
provided the most optimum growth inhibition at 4–6 weeks. We conclude that blocking
VLA-5 signaling or combining FAK inhibitors with TKI targeting BCL/ABL might be good
strategies to improve treatments in patients with Ph+ ALL. By altering Ph+ leukemia cell
interactions with the microenvironment, we may increase their susceptibility to therapy
targeting BCR/ABL.
Keywords: integrin α5β1, focal adhesion kinase, acute lymphoblastic leukemia, Philadelphia chromosome,TAE226,
bone marrow microenvironment, tyrosine kinase inhibitor
INTRODUCTION
Acute lymphoblastic leukemia bearing the Philadelphia chromo-
some (Ph+ALL) is among the most difficult types of ALL to cure.
BCR–ABL tyrosine kinase inhibitors (TKIs) such as imatinib, nilo-
tinib, or dasatinib, which target the leukemogenic tyrosine kinase
related to Philadelphia chromosome, are less effective in the treat-
ment of Ph+ALL than chronic myelogenous leukemia when used
as single agents (1). Many lines of evidence suggest that interfer-
ing with the protective effect of bone marrow microenvironment
in combination with BCR–ABL TKIs could be of benefit for the
eradication of the leukemic cells.
Integrins, a family of adhesion molecules, and tyrosine kinases
play important roles in mediating and transducing signals for cell
survival and suppressing apoptosis. Integrins are heterodimeric
signaling and adhesion molecules consisting of an alpha and
beta chain. Ligands for these receptor proteins, such as collagens,
fibronectins, and laminins, and cellular receptors, such as vascu-
lar cell adhesion molecule-1 (VCAM-1) and the intercellular cell
adhesion molecule (ICAM) family bind integrins and mediate a
variety of cell-matrix and cell–cell adhesion functions, affecting
endothelial cells, leukocytes, and leukemia or other tumor cells
behavior. Integrinα5β1, also known as very late activation antigen-
5 or VLA-5 promotes cell survival through interaction with the
extracellular matrix by activating Bcl-2, migration through acti-
vation of RhoA, and proliferation through activation of ERK, Akt,
and FAK (2). Integrin α5β1 specifically mediates the survival and
apoptosis resistance of acute lymphoblastic leukemia cells with the
Philadelphia chromosome (3–5).
Focal adhesion kinase (FAK) is a non-receptor type tyrosine
kinase that is constitutively activated in Ph+ALL. FAK can be acti-
vated by integrins, and growth factor receptors (6). FAK signaling
is critical for cell proliferation, differentiation, and apoptosis, and
is an important determinant of tumor aggressiveness (7). Inte-
grin signaling through FAK is required for certain cancer cells to
grow (8). FAK activates and stabilizes the IGF-1 receptor, which is
involved in the constitutive activation of PI3K leading to prolifer-
ation of leukemia cells (9). FAK has been shown to be activated
in Ph+ ALL (10), and is therefore an attractive molecular target.
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FAK silencing inhibited leukemogenesis in BCR/ABL-transformed
hematopoietic cells (11). This has made FAK inhibitors interesting
candidates for B cell acute lymphoblastic leukemia treatment.
We hypothesized that survival of Ph+ leukemia cells can be
inhibited by reducing signaling through VLA-5 or FAK. We test
the possibility that by interfering with VLA-5 and FAK signaling,
we will increase the susceptibility of Ph+ ALL cells to therapy
targeting BCR/ABL.
MATERIALS AND METHODS
CELL CULTURE
The human bone marrow stromal cell line, HS-5, and the Philadel-
phia chromosome positive B cell acute lymphoblastic leukemia cell
line, SUP-B15, were purchased from ATCC. HS-5 was cultured
in Dulbecco’s Modified Eagle’s Medium plus 10% fetal bovine
serum. SUP-B15 was maintained in Iscove’s Modified Dulbecco’s
Medium with 4 mM l-glutamine, 1.5 g/l sodium bicarbonate and
supplemented with 0.05 mM 2-mercaptoethanol, 20% fetal bovine
serum, and 50 U/ml penicillin/streptomycin. In order to be tracked
in vivo in animals, SUP-B15 cells were infected with lentivirus-
vector expressing system LV-luciferase (provided by Dr. Lung-Ji
Chang,Department of Molecular Genetics and Microbiology,Uni-
versity of Florida) and selected for stabilized expressing clones by
series dilution selection. The stabilized expressing luciferase cell
line was renamed SUP-LUC2.
FLOW CYTOMETRY
The expression of integrin subunits on SUP-B15 cells before or
after serum starvation was detected by flow cytometry. The expres-
sion level of integrinα5 after knocking down by integrinα5 shRNA
lentiviral transduction was confirmed by flow cytometry. Cell
apoptosis assay via PI combining with annexin-V were detected
using BD LSR II flow cytometer and analyzed with FACSDiva
software (BD Biosciences, San Jose, CA, USA). One million total
cells per sample were analyzed. SUP-B15 was cultured on top of
stromal cells HS-5 for 24 h compared without stromal cells. Ten
micrograms per liter purified no azide/low endotoxin (NA/LE)
mouse anti-human CD49e (clone: IIA1) or isotype IgG control
and imatinib or vehicle control DMSO diluted with the same con-
centration in imatinib were used as different conditions. A high
dose of imatinib of 10µM was used because SUP-B15 cells were
shown to be resistant to imatinib before with IC50 2µM (12).
CELL ADHESION ASSAY
Tissue culture-treated polystyrene 96-well microplates were coated
with human fibronectin or fibronectin fragments at a concentra-
tion between 5 and 10µg/ml on the day before use. Two hours
prior to the assay, the fibronectin coated wells were aspirated
and blocked with 2.5% bovine serum albumin (BSA) in phos-
phate buffer saline (PBS) for at least 2 h at room temperature or
overnight at 4°C. Then, the microplates were washed with 100µl
PBS. Series dilution of different antibodies purified NA/LE mouse
anti-human CD29 (clone HUTS-21), anti-human CD49d (Clone:
9F10), anti-human CD49e (clone: IIA1), and isotype IgG con-
trol with 100× of final concentrations was prepared in PBS with
Ca++ and Mg++. 50µl PBS with Ca++ and Mg++ with or
without series diluted antibodies was added to each well. Prior
to seeding, leukemia cells were stained with calcein AM (Invit-
rogen) at a final concentration of 1.25µM for 30 min, washed,
and activated with phorbol 12-myristate 13-acetate (Sigma) at
50 ng/ml for 7 min. Cells were washed immediately prior to plat-
ing. One hundred microliters of prepared cell suspension was
added to each well in triplicate. The plates were centrifuged at
411× g for 2 min to insure that the cells were in contact with
the plate surface and incubated for 30 min at 37°C. The relative
level of fluorescence of the samples prior to washing (Relative
Fluorescence Units or RFUbefore wash) was measured using fluo-
rescence Victor V microplate reader (Perkin Elmer) at excitation
wavelength of 485 nm and emission wavelength of 520 nm. Then,
the non-adherent cells were washed away with PBS twice and
the wells were refilled with 100µl PBS. The level of fluorescence
after washing (RFUafter wash) was measured using a plate reader.
The percent of adherent cells was calculated using the follow-
ing formula: [(RFUafter wash−RFUbackground)/(RFUbefore wash−
RFUbackground)]× 100. RFUbackground is the RFU for wells lacking
cells. The level of inhibition was calculated using the formula: inhi-
bition (%)= 100− 100× percent adherent cells (treated)/percent
adhesion of cells (without treatment).
CELL PROLIFERATION ASSAYS
Cell proliferation was analyzed by MTT assay using the Cell Prolif-
eration Kit I (MTT; Roche) as recommended by the manufacturer.
SUP-B15 cells were seeded onto 96-well plates at a concentration of
2× 104 cells/well. TAE226 stock buffer was suspended in DMSO at
10 mM. A final concentration for TAE226 from 10 to 0.02µM was
prepared by serial dilution and added to the seeded cells with a final
DMSO concentration of <0.1%. After 24, 48, and 72 h, cells were
incubated for 4 h with 0.5 mg/ml MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide, a tetrazole] dye in complete
cell culture medium. After solubilization of the purple formazan
crystals, absorbance was measured at 570 nm (background wave-
length, 650 nm) using a plate spectrophotometer. We used Prism
to calculate the IC 50 dosage.
INTEGRIN α5 KNOCK-DOWN BY shRNA LENTIVIRAL TRANSDUCTION
The spinning infection method was used to enhance the effi-
ciency of lentiviral particle transduction. SUP-LUC2 cells growing
in exponential phase were cultured overnight in fresh complete
medium. The medium was replaced with a polybrene/media mix-
ture at a final concentration of 5µg/ml polybrene immediately
before lentivirus infection. Human integrin α5 shRNA lentivi-
ral particles (Catalog # sc-29372-V, Santa Cruz) were thawed at
room temperature and added to leukemia cell suspension in 15 ml
conical tubes and were spun at 800× g (2500 rpm) for 90 min
at 37°C. After spinning, the supernatant was aspirated and the
cells were replenished in the fresh culture medium for ~48 h. Two
days later, stable clones were selected using complete medium with
puromycin. Two weeks later, leukemia cells were cultured with reg-
ular medium without puromycin. During selection, the medium
containing puromycin was changed once a week.
In order to select stable clones expressing the shRNA to knock-
down integrin α5 gene expression via puromycin dihydrochloride
(sc-108071, Santa Cruz) selection, a titration of puromycin con-
centrations from 0 to 2.5µg/ml were used to incubate SUP-LUC2
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cells for culture over 2 weeks. After 1 week, the concentrations of
puromycin to kill cells and the one in which cells were still alive
were noted. At the 2 week time point, the wells with all dead cells
were noted. The minimum level of puromycin dose, 0.8µg/ml,
which killed SUP-LUC2 cells by week 1 and in which there were
no surviving cells/regrowth at 2 weeks, was chosen for selection.
QUANTITATIVE REVERSE TRANSCRIPTASE-POLYMERASE CHAIN
REACTION
Total RNA was extracted by RNeasy Mini Kit (Qiagen, Valencia,
CA, USA). The yield of purified RNA was determined by a spec-
trophotometer (NanoDrop 2000; Thermo Scientific, Wilmington,
DE, USA). cDNA was prepared from 1.0µg of total RNA with
AffinityScript™ QPCR cDNA Synthesis Kit (Stratagene, La Jolla,
CA, USA). QPCR amplification of cDNA was performed using
the Brilliant® II SYBR® Green QPCR Master Mix with Stratagene
Mx3000P. Primers for integrin α5 was purchased from Santa Cruz
(Catalog # sc-29372-PR). GAPDH primers forward TGCACCAC-
CAACTGCTTAGC and reverse GGCATGGACTGTGGTCATGAG
were used as control. The cycle threshold (Ct) of the target
gene (integrin α5) was normalized to the chosen reference gene
GAPHD. Relative quantification, R= 2−(∆Ct sample−∆Ct control).
Result showed the fold change normalized to SUP-LUC2 cells.
WESTERN BLOTTING
For Western blotting, 0.5 to 1× 107 cells were washed in cold
PBS. Cells were lysed for 30 min in cell extraction buffer (Invit-
rogen, Camarillo, CA, USA) supplemented with 1 mM PMSF,
protease inhibitor cocktail (Roche), and 1:100 diluted phosphatase
inhibitor cocktail 2 (Sigma). Clear lysate was obtained by cen-
trifugation at 13,000 rpm for 10 min at 4°C. Protein concentration
was analyzed with Pierce™ BCA Protein Assay Kit (Pierce, Rock-
ford, IL, USA). Fifty to hundred micrograms of protein were
mixed with 6× SDS sample buffer and boiled for 10 min before
loading. Proteins were resolved on polyacrylamide SDS gels (SDS-
PAGE) and transferred to nitrocellulose (membrane Hybond-C
super, Millipore). The membrane was blocked for 1 h at room
temperature in Tris-buffered saline (TBS) containing 5% fat-free
milk and then was probed overnight at 4°C overnight with the
FAK, phospho-FAK (Tyr397) antibody, phospho-p44/42 MAPK
(Erk1/2), and phospho-Akt (Thr308) antibodies (Cell Signaling),
β-actin antibody (Santa Cruz), and mouse Anti-Human CD49e
(BD Biosciences) at the concentration suggested by manufacturers
in TBS, 0.1% Tween, 3% fat-free milk, and 3% BSA (Euromedex).
After incubation for 1 h at room temperature with either anti-
mouse or anti-rabbit IgG antibody coupled to horseradish perox-
idase, detection was achieved using a chemiluminescent substrate
(SuperSignal, Amersham Pharmacia Biotech).
ANIMAL STUDIES
Mouse strains NOD/LtSz-scid/J (NOD/SCID) and NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ, commonly known as NOD/SCID gamma
mice (NSG), were bred and housed in the specific pathogenic-
free (SPF) facility at the UF Health Cancer Center. The breeding
pairs were purchased from Jackson Laboratories (Bar Harbor,
Maine). These studies were approved by the University of Florida
Institutional Animal Care and Use Committee.
Short term engraftment study with integrin α5 antibody in NOD/SCID
mice
Before injection, SUP-B15 cells were incubated with anti-integrin
α5 antibody clone IIA1 (BD Biosciences) or clone P1D6 (Milli-
pore) at a concentration of 5µg/ml or vehicle for 30 min. Without
washing out the antibody, leukemia cells were injected into the
tail vein after sublethal irradiation with 250cG from a cesium137
source. Twenty-four hours later, the number of human cells in
the peripheral blood, bone marrow, and spleen was analyzed by
flow cytometry after animals were euthanized. Human cells were
recognized by flow cytometry using anti-human CD45 antibody
conjugated to APC.
Studying the effect of echistatin pretreatment on leukemia
development
Before injection, SUP-LUC2 cells were resuspended in PBS buffer
at a concentration of 25× 106/ml and incubated with 62.5µg/ml
Echistatin (a potent non-specific inhibitor of integrin/ligand bind-
ing, blocking αIIβ3, αvβ3, and α5β1 integrin) or vehicle for 1 h.
Echistatin was washed out by resuspension in the same con-
centration of normal saline plus 0.5% albumin before injec-
tion. NSG mice were sublethally irradiated with 250cG from a
cesium137 source. Each animal was injected with SUP-LUC2 cells
by tail vein within 6 h after irradiation. Starting from 1 week after
leukemia cells injection, animals were injected with d-luciferin.
Animals were imaged weekly with Xenogen IVIS Imaging Sys-
tem 200 Series (IVIS, Xenogen) and animals receiving cells pre-
treated with echistatin were compared to those treated with
vehicle.
Studying the effect of knocking down integrin α5 on leukemia
development
After stable clone selection, SUP-LUC2 α5 knock-down clone
number 10 (named SUP-LUC2 α5–10) was chosen for animal
engraftment study. We irradiated NOD/SCID mice and injected
them with 5× 106 leukemia cells. Weekly imaging started 2 weeks
after injection and continued for 8 weeks.
Studying the effect of the FAK inhibitor TAE226 on leukemia cell
engraftment
NOD/SCID gamma mice were sublethally irradiated as before.
Each animal was injected with 5× 106 in SUP-LUC2 cells by tail
vein in 200µl normal saline plus 0.5% human albumin within
6 h after irradiation. Then animals were divided into four groups.
Control animals were treated with vehicle methylcellulose. TAE226
group animals were treated with 30 mg/kg TAE226 diluted in
200µl methylcellulose by oral gavage. In TKI group, animals
were treated with nilotinib obtained from Novartis Oncology at a
dose of 20 mg/kg in 100µl vehicle by oral gavage. Nilotinib was
suspended in 0.5% hydroxypropylmethylcellulose aqueous solu-
tion containing 0.05% Tween 80 at a concentration of 4 mg/ml.
Combination group animals were treated with TAE226 and nilo-
tinib at the same concentration as previous group. Treatment
commenced 2 weeks after leukemia cells were injected. Animals
received treatment 5 days per week with 2 days off for total of
2 weeks. Imaging was started 2 weeks after leukemia cell injection
and then weekly.
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In vivo imaging
For non-invasive imaging of SUP-LUC2 cells, anesthetized mice
were injected with 150 mg/kg of d-luciferin (potassium salt,
Xenogen Corp., Alameda) intraperitoneally 10–15 min before
imaging and were imaged using the Xenogen IVIS Imaging Sys-
tem 200 Series with total imaging time of 2 min. Total body
bioluminescence was quantified as described (13).
Mice were sacrificed when they became moribund or unable to
obtain food or water or if they lost >20% of their body weight.
STATISTICAL ANALYSIS
Results are expressed as means (SD) or means± SD of three sep-
arate replicate experiments unless otherwise indicated. Levels of
significance were evaluated by a two-tailed paired Student’s t -test,
and p< 0.05 was considered significant.
RESULTS
INTEGRIN α5β1 EXPRESSION WAS INCREASED IN PH+ LEUKEMIA
CELLS AFTER SERUM STARVATION
Leukemia cells can adapt to adverse environments, such as depri-
vation of nutrients or oxygen, resulting in aggressive growth. In
Figure 1, we show that Ph+ leukemia cells increased the expres-
sion level of integrin α5β1 under conditions of serum starvation.
The percentage of cells expressing the α5 subunit increased from
12.5% before to 84.5% after serum starvation. The mean fluores-
cent intensity (MFI) for the α5 subunit also increased from 106
before to 237 arbitrary units of fluorescence (a.u.) after serum
starvation. The percentage of cells expressing the β1 subunit did
not increase in response to serum starvation (25.3 before vs. 32.
0% after). However, MFI increased significantly after serum star-
vation from 329 to 556 a.u. The percentage of cells expressing the
α4 subunit increased from 25.6 to 52.2% and MFI from 91 to 110
after serum starvation.
TREATMENT WITH THE INTEGRIN α5 SUBUNIT ANTIBODY INHIBITED
THE ADHESION OF PH+ LEUKEMIA CELLS TO HUMAN FIBRONECTIN,
AND ENHANCED THE KILLING OF IMATINIB
Integrin is expressed by mouse and human long-term repop-
ulating hematopoietic cells. In normal long-term repopulating
hematopoietic cells, integrin signaling that results from α5β1 inte-
grin binding to fibronectin protects these cells from apoptosis. To
better understand the role of different integrin subunits on Ph+
leukemia cells interaction with fibronectin, we used a cell adhe-
sion assay to check which subunit most sensitively affected the
interaction of Ph+ leukemia cells with fibronectin. Result showed
that the α5 subunit inhibitory antibody (CD49e) was the only one
that significantly inhibited the adhesion of Ph+ leukemia cells
to fibronectin with adhesion percentage of 6.6± 3.8 compared
with control IgG 44.8± 7.9, p< 0.01 (Figure 2A). Interestingly,
we found that antibody to CD29 increased the adhesion rate of
Ph+ leukemia cells to fibronectin, with 61.6± 22.1% binding vs.
44.8± 7.9% of control cells, p< 0.05.
To investigate whether bone marrow stromal cells protected
Ph+ leukemia cells from imatinib induced apoptosis, we cul-
tured Ph+ ALL cells on the HS-5 human bone marrow stromal
cell line. Cells were grown in the presence or absence of ima-
tinib and the integrin α5 inhibitory antibody. Cells cultured with
FIGURE 1 |The expression level of integrin α5 subunit in Ph+ leukemia
cell line SUP-B15 is significantly increased after serum starvation.
(A) The percentages of cells expressing integrin α4, α5, and β1 subunits
before and after serum starvation for 7 h detected by flow cytometry.
(B) The mean fluorescent intensity (MFI) of integrin α4, α5, and β1 subunits
from whole alive cell population before and after serum starvation for 7 h
detected by flow cytometry.
imatinib or HS-5 alone served as controls. We identified Ph+
leukemia cells using the human CD38 antibody and analyzed
apoptosis with Annexin-V combined with propidium iodide by
flow cytometry. As shown in Figures 2B,C, after culture on HS-
5 cells for 24 h, the apoptosis rate of leukemia cells SUP-B15
decreased from 29.4± 2.3 to 16.7± 3%, p< 0.05. HS-5 com-
bined with imatinib decreased apoptosis rate from 37.4± 1.2%
without HS-5 to 25.7± 3.3%, but this result was not statisti-
cally significant, p= 0.45. When inhibitory antibody to integrin
α5 was combined with imatinib to treat Ph+ leukemia cells
cultured on stromal cells, the apoptosis rate 38.0± 8.0% signif-
icantly increased compared with imatinib by itself 25.7± 3.3%,
p< 0.05. There was no significant difference for the leukemia
apoptosis rate between cells cultured with and without HS-5
cells when α5 antibody was included (38.0± 8.0 vs. 38.6± 1.4,
p> 0.05). This confirmed that the protective effect of stro-
mal cells was mediated through the α5 integrin, and demon-
strated the synergistic effect of integrin α5 antibody with
imatinib.
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FIGURE 2 | Integrin α5 subunit antibody inhibits the adhesion of Ph+
leukemia cells to human fibronectin and enhances the killing of imatinib.
(A) Cell adhesion assay showed that α5 subunit inhibitory antibody (CD49e,
clone IIA1 BD Biosciences) was the only tested integrin antibody that
significantly inhibited the adhesion of Ph+ leukemia cells to fibronectin with
adhesion percentage of 6.6±3.8% compared with control IgG of
44.8± 7.9%, p<0.01. (B). Annexin-V plus PI by flow cytometry. (i) P2 gate
identifies the CD38 positive cell population representing SUP-B15 Ph+
leukemia cells. (ii) Ph+ leukemia cells grown on HS-5 stromal cells. (iii) Ph+
leukemia cells treated with 10µM imatinib (IM). (iv) SUP-B15 cultured with
stromal cells treated with 10µM imatinib. (v) SUP-B15 cultured with stromal
cells treated with 10µM imatinib and 10µg/ml anti-α5 Ab. (C) Quantitative
analysis for apoptosis rate of different conditions. *After culture on HS-5 cells
for 24 h, the apoptosis rate of leukemia cells SUP-B15 decreased from
29.4±2.3 to 16.7±3%, p<0.05. #When inhibitory antibody to integrin α5
was combined with imatinib to treat Ph+ leukemia cells cultured on stromal
cells, the apoptosis rate 38.0±8.0% was significantly increased compared
with imatinib by itself 25.7±3.3%, p<0.05.
BLOCKING INTEGRIN α5 REDUCED THE ENGRAFTMENT OF PH+
LEUKEMIA CELLS IN IMMUNODEFICIENT MICE
To demonstrate the role of integrins in enhancing the survival
of Ph+ leukemia cells in vivo, we first performed experiments to
study the effect of integrin inhibition on short term Ph+ leukemia
cell engraftment. Echistatin is a potent non-specific inhibitor of
integrin/ligand binding, blocking αIIβ3, αvβ3, and α5β1 integrin
(14, 15). We used echistatin to test if blocking integrin α5β1
integrin could affect the engraftment of Ph+ leukemia cells in
immunodeficient mice. As shown in Figures 3A,B, after incu-
bation with echistatin for about 30 min, the engraftment was
significantly delayed from day 7 to 1 month post injection. Echis-
tatin did not significantly affect the viability of injected cells (data
not shown).
To understand how specifically integrin α5 affects the in vivo
effect, we incubated the Ph+ leukemia cells with two types of inte-
grin α5 inhibitory antibodies. We then injected leukemia cells into
NOD/SCID mice to observe the effect on short term engraftment.
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FIGURE 3 | Blocking integrin α5 affects the engraftment of Ph+
leukemia cells in immunodeficient mice. (A) The incubation for 1 h of
Ph+ leukemia cells with disintegrin, a peptide inhibitor of integrins,
impaired the engraftment of leukemia in NSG mice. Representative
figures of n=2 showed bioluminescence imaging from day 7 to 28 after
inoculation of leukemia cells. (B) Animal total body bioluminescence was
measured using the Xenogen IVIS Imaging System 200 Series with total
imaging time of 2 min and compared with control animals that received
cells that were not treated with Echistatin. (C) Anti-integrin α5 inhibitory
antibodies clone IIA1 (BD Biosciences) and clone P1D6 (Millipore)
decreased the engraftment of Ph+ leukemia cells in the bone marrow of
NOD/SCID mice (n=2).
Twenty-four hours after injection, mice (n= 2) were sacrificed
and peripheral blood, spleen, and bone marrow samples were
obtained and analyzed by flow cytometry. We found that incubat-
ing leukemia cells with antibodies that block α5 integrin decreased
the engraftment percentage from 5.3 to 1–2% compared with
isotype control in the bone marrow, and from 3.5 to 1.2% in
the peripheral blood (Figure 3C). Most of the leukemia cells
were sequestered in the spleen. The percentage of leukemia cells
increased from 23.4% when incubated with an isotype control to
35.2 or 45.9% with two different clones of integrin α5 antibodies.
KNOCKING DOWN INTEGRIN α5 DELAYED THE LONG-TERM
ENGRAFTMENT AND PROGRESSION OF PH+ LEUKEMIA CELLS IN
IMMUNODEFICIENT MICE
To further test the role of integrin α5 on the long-term engraft-
ment of Ph+ cells in the bone marrow, the integrin α5 subunit
was knocked down by human integrin α5 shRNA lentiviral parti-
cles. We selected the Ph+ leukemia cell clone (clone 10) with the
highest degree of knock-down of integrin α5 by real-time quanti-
tative PCR assay (Figure 4A). Western blot confirmed reduction of
integrin α5 protein expression (Figure 4B). Flow cytometry also
demonstrated reduced MFI (Figure 4C).
We used luciferase to monitor the engraftment level of Ph+
leukemia cells with and without knock-down of the α5 integrin
in vivo in NOD/SCID mice. Five weeks post inoculation, the
levels of bioluminescence in mice receiving Ph+ leukemia cells
with integrin α5 knock-down were significantly lower than in
the control group [mean (SD) radiance vs. control, 0.7 (0.3) vs.
1.3 (0.2)× 106 p/s/cm2/sr, p< 0.05 on day 37]. Since NOD/SCID
mice have some NK cell and macrophage function, the xenografted
human leukemia cell percentage is lower in NOS/SCID mice than
that in NSG mice. Our experiments also confirmed this phenom-
enon. It also took longer time to show the engraftment differences
between integrin knock-down group and control group when
using NOS/SCID mice. The levels of bioluminescence became
most significantly different 2 months post inoculation between
the α5 knock-down group and the control group [mean (SD) radi-
ance vs. control, 5.3 (0.1) vs. 2.1 (0.2)× 106 p/s/cm2/sr, p< 0.01
at 2 months] (Figures 4D,E).
THE FAK INHIBITOR TAE226 INHIBITED PH+ LYMPHOBLASTIC
LEUKEMIA PROLIFERATION IN VITRO
Focal adhesion kinase is the downstream signal of integrin α5β1.
TAE226 is a novel small molecule ATP competitive inhibitor of
FAK and tyrosine kinase activity of insulin-like growth factor
I (16, 17). Here we used serial dilution of TAE226 to observe
how it affected the leukemia cell proliferation. TAE226 signif-
icantly inhibited leukemia cell proliferation at concentrations
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FIGURE 4 | Knocking down integrin α5 delayed the engraftment of Ph+
leukemia cells in immunodeficient NOD/SCID mice. (A) Real-time QPCR
assay showed that we had successfully knocked down the expression level of
the integrin α5 knocking in clone 10. The cycle threshold (Ct) of the target
gene (integrin α5) was normalized to the chosen reference gene GAPHD.
Relative quantification, R=2−(∆Ct sample−∆Ct control). Result shows the fold change
normalized to SUP-LUC2 cells. (B) Western blot showed a reduced protein
expression level of integrin α5 in clone 10. (C) Flow cytometry showed
reduced mean fluorescent intensity of integrin α5 in clone 10.
(D) Representative figures showed bioluminescent imaging at 2 weeks, and
5–8 weeks post leukemia cells inoculation. (E) Animal total body
bioluminescence was quantified to compare with control. **The levels of
bioluminescence became most significantly different 2 months post
inoculation between the α5 knock-down group and control group [mean (SD)
radiance vs. control, 5.3 (0.1) vs. 2.1 (0.2)×106 p/s/cm2/sr, p<0.01 at
2 months, n=3.].
above 75 nM. Figure 5A shows the dose–response curves of effects
of TAE226 on Ph+ ALL leukemia growth with an IC 50 dosage
of 0.26µM. To explore which signaling pathway is involved in
TAE226-induced apoptosis, we dissected out downstream mole-
cules of FAK by Western blot. TAE226 inhibited phosphorylation
of FAK in a dose- and time-dependent manner in Ph+ leukemia
cells. Erk1/2 activation was also suppressed, whereas the inhibition
of Akt activity was modest (Figures 5B,C).
FAK INHIBITOR TAE226 SYNERGIZED WITH NILOTINIB TO BLOCK PH+
LYMPHOBLASTIC LEUKEMIA GROWTH IN VIVO
We confirmed a potent inhibitory effect of TAE226 on Ph+
leukemia cell growth in vitro. For the next step, we used immuno-
compromised NSG mice to generate human leukemia xenografts.
The animals were treated with an oral administration of either
TAE226 (30 mg/kg), TKI nilotinib, the combination of TAE226
and nilotinib or methylcellulose as vehicle control. The daily
administration started 2 weeks after inoculation and continued
for 2 weeks (days 1–14 with 2 days break each week). Results in
Figure 6 showed that even though treatment with FAK inhibitor
TAE226 alone did not significantly inhibit leukemia growth in
mice by body bioluminescence [mean (SD) radiance vs. control,
3386 (2294) vs. 4979 (4609)× 106 p/s/cm2/sr, p= 0.38 on day 44],
the FAK inhibitor TAE226 in combination with TKI nilotinib
provided the most optimum growth inhibition 4–6 weeks post
inoculation. On day 30 post inoculation, mean radiance (SD) in
animals receiving nilotinib in combination with TAE226 was sig-
nificantly lower than that in the control group [160 (121) vs. 498
(306)× 106 p/s/cm2/sr,p= 0.02]. On day 37 post inoculation, lev-
els of bioluminescence in the combination treatment group were
most significantly reduced compared with the control group [418
(221) vs. 1908 (1281)× 106 p/s/cm2/sr, p< 0.01]. There was still
a significant difference on day 44 with animals from the control
group [938 vs. 4979× 106 p/s/cm2/sr,p= 0.03]. Animals receiving
nilotinib alone only showed significant differences on day 37 post
inoculation compared with the control group, with mean radiance
(SD) [752 (391) vs. 1908 (1281), p= 0.01].
DISCUSSION
In this study, we report that integrin α5β1 and its downstream
signal FAK may be good targets for developing new strategies to
treat Ph+ ALL.
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FIGURE 5 | Effect of FAK inhibitors on Ph+ALL. (A) TAE226 inhibits
SUP-B15 cell growth with an IC50 0.4µM. (B) Western blot with protein
obtained from SUP-B15 cells, which were cultured with different
concentration of TAE226 from 0 to 10µM for 1 h. (C) Western blot with
protein obtained from SUP-B15 cells, which were cultured with 1µM
TAE226 from 1 to 24 h. (B,C) Western blot showed that TAE226 reduced
phosphorylation of FAK and AKT, ERK1/2, which are downstream in the
FAK signaling pathway.
FIGURE 6 |TAE226 reduced Ph+ lymphoblastic leukemia progression
in NSG mice. (A) Animal experiment scheme. (B) Animal bioluminescent
imaging at 3–8 weeks after inoculation of leukemia cells. (C) Animal total
body bioluminescence was quantified for comparison (N =4 ~ 6). *On day
30 and 44 post inoculation, mean radiance (SD) in animals receiving
nilotinib in combination with TAE226 was significantly lower than that in
the control group, p<0.05. On day 37 post inoculation, animals receiving
nilotinib alone only showed significant differences compared with the
control group, p=0.01. **On day 37 post inoculation, levels of
bioluminescence in the combination treatment group were most
significantly reduced compared with the control group [418 (221) vs. 1908
(1281)×106 p/s/cm2/sr, p<0.01].
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INTEGRIN α5β1 IS A SPECIFIC TARGET FOR PH+ ALL
Through interaction of integrin α5β1 (VLA-5) with fibronectin,
leukemia cells adhere to marrow stroma and become quiescent and
resistant to chemotherapy (18, 19). Acute lymphoblastic leukemia
patients with Ph+ have been shown to express very high levels
of both VLA-4 and VLA-5 (3). Introduction of BCR/ABL into
hematopoietic cell lines enhances adhesion through VLA-5 by
inside-out signal (4). Our results in Figure 1 showed that both
the percentage and intensity of integrin α5 subunit increased sig-
nificantly more than the α4 subunit in Ph+ ALL cells after serum
starvation. Upregulation of VLA-5 under conditions of stress may
be one of the reasons Ph+ leukemia has been difficult to treat.
The upregulation of integrin α5β1 can protect leukemia cells
from apoptosis and provide a growth advantage relative to nor-
mal hematopoietic cells. For instance, it has been shown that α5β1
integrin upregulated the resistance to TNF induced apoptosis in
adherent leukemia cells (5).
van der Loo and colleagues have shown that mouse long-term
in vivo repopulating stem cells and primitive human NOD/SCID
mouse repopulating cells, bind to the extracellular matrix pro-
tein fibronectin through VLA-5 in vitro. This binding is specific
and can be inhibited by antibodies to VLA-5 (20). In Figure 2 we
show that α5 subunit antibody specifically blocked the adhesion
of Ph+ ALL cells to fibronectin. This indicates that integrin α5β1
is specific to Ph+ALL cells as well as in the normal hematopoietic
stem/progenitor cells and could be an important treatment target
for this type leukemia. So targeting α5β1 might be able to block the
Ph+ leukemia cells adhesion to bone marrow stroma fibronectin
and induce apoptosis when combined with TKIs. However, off
target effects on hematopoietic stem cells could be a problem and
would have to be considered in developing such a strategy.
In order to confirm the specific protective effect of integrin
α5β1 signaling through interaction with FN for Ph+ leukemia
cells, we cultured SUP-B15 on the human bone marrow stromal
cell line HS-5. We found that the apoptosis rate of SUP-B15 cells
decreased when cultured on stroma. Integrin α5 inhibitory anti-
body blocked the protective effect of stromal cells and synergized
with imatinib to induce apoptosis.
As it is reviewed in Aoudjit’s article, ECM/integrin signal-
ing protects tumor cells from drug-induced apoptosis (21). Dif-
ferent integrin family members might be involved in different
types of tumors. For instance, the α4β1 integrin interaction
with fibronectin prevents apoptosis in B cell chronic lympho-
cytic leukemia (22). Blocking integrin alpha4 can sensitize drug
resistant of pre-B acute lymphoblastic leukemia to chemotherapy
(23). The interaction between VLA-4 on acute myeloid leukemic
cells and fibronectin on stromal cells is crucial in minimal residual
disease and for acute myelogenous leukemia prognosis (24). The
α2β1 integrin was shown to be important for integrin-mediated
attachment to collagen type I during metastasis of breast cancer
cells to the bone (25). α4β1 integrin was involved in increased
peritoneal metastasis and αvb3 in tumor proliferation for ovarian
cancer (26). Our data suggest that integrin α5β1 is a promising
target for Ph+ ALL.
Integrin α5β1 (VLA-5) is the key adhesion molecule for lym-
phocyte homing. In order to further investigate the importance
of integrin α5β1 on Ph+ ALL cells, we incubated Ph+ leukemia
cells with disintegrin, a peptide inhibitor of integrins, and specific
α5 inhibitory antibody, and specially knocked down α5 subunit
by shRNA and then tested the Ph+ leukemia engraftment in
immunodeficient mice. Using two types of immunodeficient mice,
NOD/SCID and NSG, we found that every method we used to
block integrinα5 impaired or delayed the engraftment of leukemia
in immunodeficient mice. Although, since the engraftment levels
were different between the two types of mice, it took longer for
NOD/SCID mice to show the differences in engraftment since
the overall engraftment levels were lower. This result indicates
that integrin α5β1 (VLA-5) is important for Ph+ leukemia cells’
engraftment into the bone marrow.
Since the integrin α5β1 inhibitor is not commercially avail-
able and a large amount of integrin α5β1 antibodies are needed
to be purified for in vivo experimental usage, we are not able to
directly test the effects of integrin α5β1 inhibitor or antibodies in
the treatment for Ph+ leukemia using our animal model. Devel-
oping a specific antagonist for integrin α5β1 is our next study
direction. In order to test our hypothesis that blocking this pathway
could improve leukemia outcome, we used TAE226, the inhibitor
of FAK, an integrin downstream factor, in combination with the
TKI, nilotinib, to determine whether they would synergize.
FAK INHIBITOR TAE226 PLAYS A SYNERGISTIC ROLE WITH NILOTINIB
IN INHIBITING PROGRESSION OF PH+ LEUKEMIA IN XENOGRAFTS
Focal adhesion kinase is a non-receptor type tyrosine kinase that
is activated from integrins and FAK signaling is critical for tumor
growth. FAK is constitutively activated in Ph+ ALL by the BCR–
ABL translocation (10). FAK silencing inhibits leukemogenesis in
BCR/ABL-transformed hematopoietic cells (D10). TAE226 is a
novel low-molecular weight inhibitor of FAK. TAE226 inhibits
the phosphorylation of FAK (27). We used TAE226 to study how
it affects Ph+ leukemia growth in vitro. As shown in Figure 5,
TAE226 significantly inhibited leukemia cell growth at a con-
centration above 75 nM with an IC 50 of 0.26µM. Western blot
showed that TAE226 inhibited phosphorylation of FAK in a dose-
and time-dependent manner and suppressed Erk1/2 activation
in Ph+ leukemia cells. TAE226 did not significantly inhibit the
Ph+ leukemia growth at a concentration of 30 mg/kg in vivo in
a xenografted animal model. However, when combined with the
BCR–ABL TKI nilotinib,TAE226 at 30 mg/kg synergized with nilo-
tinib to provide the most optimum growth inhibition between 4
and 6 weeks post inoculation.
TAE226 has demonstrated anti-tumor activity in experimental
models in ovarian cancer, gliomas, esophageal, and breast can-
cer. Ozkal et al., have performed a comprehensive study of FAK
expression in normal lymphoid tissues and leukemias/lymphomas
by immunohistochemistry and found that FAK was present in the
majority of cases of B-(75%) and absent in T-(0%) lymphoblas-
tic leukemias/lymphomas (28). Our study supports that FAK is a
good target for Ph+ ALL.
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